Upadacitinib Tops Abatacept for RA Refractory to DMARDs

FRIDAY, Oct. 16, 2020 -- Upadacitinib is superior to abatacept for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (DMARDS), according to a study published online Oct. 15 in the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news